Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SRC001
MIFTS: 30

Sarcomatoid Mesothelioma

Categories: Cancer diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Sarcomatoid Mesothelioma

About this section

MalaCards integrated aliases for Sarcomatoid Mesothelioma:

Name: Sarcomatoid Mesothelioma 12 15 73
Malignant Fibrous Mesothelioma 12
Spindled Mesothelioma 12

Classifications:

MalaCards categories:
Global: Cancer diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:4488
NCIt 50 C45655
SNOMED-CT 68 54443001
UMLS 73 C0334513
Sources

Summaries for Sarcomatoid Mesothelioma

About this section
MalaCards based summary : Sarcomatoid Mesothelioma, also known as malignant fibrous mesothelioma, is related to malignant epithelial mesothelioma and lymphohistiocytoid mesothelioma. An important gene associated with Sarcomatoid Mesothelioma is THBD (Thrombomodulin), and among its related pathways/superpathways is Primary Focal Segmental Glomerulosclerosis FSGS. The drugs Cisplatin and Vinblastine have been mentioned in the context of this disorder. Affiliated tissues include t cells, lung and spinal cord, and related phenotypes are Increased transferrin (TF) endocytosis and cardiovascular system

Sources

Related Diseases for Sarcomatoid Mesothelioma

About this section

Diseases related to Sarcomatoid Mesothelioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 54)
# Related Disease Score Top Affiliating Genes
1 malignant epithelial mesothelioma 30.2 THBD WT1
2 lymphohistiocytoid mesothelioma 30.1 CDKN2A THBD
3 malignant pleural mesothelioma 29.6 CDKN2A NKX2-1 THBD WT1
4 sarcoma 10.2
5 malignant biphasic mesothelioma 10.1 THBD WT1
6 rete testis adenocarcinoma 10.1 NKX2-1 THBD
7 benign mesothelioma 10.1
8 rete testis neoplasm 10.1 NKX2-1 THBD
9 senile angioma 10.1 THBD VIM
10 cystic nephroma 10.1 VIM WT1
11 metanephric adenoma 10.1 VIM WT1
12 desmoplastic small round cell tumor 10.1 VIM WT1
13 sertoli cell tumor 10.1 VIM WT1
14 ovarian brenner tumor 10.1 THBD WT1
15 fallopian tube squamous cell carcinoma 10.1 CDKN2A WT1
16 melanomatosis 10.1 CDKN2A WT1
17 pericardial mesothelioma 10.1 THBD VIM
18 extraskeletal ewing sarcoma 10.1 NKX2-1 VIM
19 breast giant fibroadenoma 10.0 CDKN2A WT1
20 mucinous adenocarcinoma 10.0 CDKN2A NKX2-1
21 hidradenocarcinoma 10.0 NKX2-1 VIM
22 papillary adenocarcinoma 10.0 NKX2-1 VIM
23 rhabdoid tumor predisposition syndrome 1 10.0 VIM WT1
24 malignant peritoneal mesothelioma 10.0 CDKN2A VIM
25 mucinous bronchioloalveolar adenocarcinoma 10.0 CDKN2A NKX2-1
26 pleural cancer 10.0 CDKN2A WT1
27 ameloblastic carcinoma 10.0 CDKN2A VIM
28 dystonia 11, myoclonic 10.0 NKX2-1 VIM
29 endometrial mucinous adenocarcinoma 10.0 CDKN2A VIM
30 bile duct adenoma 10.0 CDKN2A VIM
31 bronchiolo-alveolar adenocarcinoma 10.0 MUC4 NKX2-1
32 pleomorphic liposarcoma 10.0 CDKN2A VIM
33 liposarcoma 10.0 CDKN2A VIM
34 diaphragmatic hernia, congenital 10.0 NKX2-1 WT1
35 cavernous hemangioma 10.0 NKX2-1 VIM
36 endocervical adenocarcinoma 10.0 CDKN2A VIM
37 adenosquamous carcinoma 10.0 MUC4 NKX2-1
38 biliary tract neoplasm 10.0 CDKN2A MUC4
39 sarcoma, synovial 10.0
40 chondromyxoid fibroma 10.0 CDKN2A VIM
41 leiomyosarcoma 9.9 VIM WT1
42 peritoneal mesothelioma 9.9 CDKN2A THBD WT1
43 small cell carcinoma 9.9 CDKN2A NKX2-1
44 dermoid cyst 9.9 NAPSA VIM
45 ewing sarcoma 9.8 CDKN2A VIM WT1
46 chordoma 9.8 CDKN2A VIM
47 adenomatoid tumor 9.8 NKX2-1 THBD VIM WT1
48 papillary adenoma 9.8 NAPSA NKX2-1 VIM
49 malignant peripheral nerve sheath tumor 9.8 CDKN2A VIM
50 respiratory system cancer 9.7 CDKN2A NAPSA NKX2-1

Graphical network of the top 20 diseases related to Sarcomatoid Mesothelioma:



Diseases related to Sarcomatoid Mesothelioma
Sources

Symptoms & Phenotypes for Sarcomatoid Mesothelioma

About this section

GenomeRNAi Phenotypes related to Sarcomatoid Mesothelioma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased transferrin (TF) endocytosis GR00363-A 9.1 CDKN2A MUC4 NAPSA NKX2-1 THBD VIM

MGI Mouse Phenotypes related to Sarcomatoid Mesothelioma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.55 CDKN2A NKX2-1 THBD VIM WT1
2 reproductive system MP:0005389 9.35 CDKN2A NKX2-1 THBD VIM WT1
3 respiratory system MP:0005388 9.02 CDKN2A NKX2-1 THBD VIM WT1
Sources

Drugs & Therapeutics for Sarcomatoid Mesothelioma

About this section

Drugs for Sarcomatoid Mesothelioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 58)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 2,Phase 1 15663-27-1 2767 441203 84093
2
Vinblastine Approved Phase 2 865-21-4 241903 13342
3
leucovorin Approved Phase 2,Phase 1 58-05-9 6006 143
4
Methotrexate Approved Phase 2 59-05-2, 1959-05-2 126941
5
Vinorelbine Approved, Investigational Phase 2 71486-22-1 60780 44424639
6
Gemcitabine Approved Phase 2 95058-81-4 60750
7
Belinostat Approved, Investigational Phase 2 866323-14-0
8
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
9
Pemetrexed Approved, Investigational Phase 2,Phase 1 150399-23-8, 137281-23-3 446556 60843
10
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
11
Trioxsalen Approved Phase 2 3902-71-4 5585
12
Bevacizumab Approved, Investigational Phase 2 216974-75-3
13
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
14
Nicotinamide Approved, Investigational Phase 2 98-92-0 936
15
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
16
Pembrolizumab Approved Phase 2 1374853-91-4
17
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2,Phase 1 59-30-3 6037
18
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
19
Glutamic Acid Approved, Nutraceutical Phase 1, Phase 2 56-86-0 33032
20
Cediranib Investigational Phase 2,Phase 1 288383-20-0 9933475
21
Maleic acid Experimental Phase 2,Phase 1 110-16-7 444266
22
Vatalanib Investigational Phase 2 212141-54-3 151194
23 Antirheumatic Agents Phase 2
24 Nucleic Acid Synthesis Inhibitors Phase 2,Phase 1
25 Immunologic Factors Phase 2
26 Antimetabolites, Antineoplastic Phase 2
27 Antineoplastic Agents, Phytogenic Phase 2
28 Vitamin B Complex Phase 2,Phase 1
29 Folic Acid Antagonists Phase 2,Phase 1
30 Folate Phase 2,Phase 1
31 Immunosuppressive Agents Phase 2
32 Antimitotic Agents Phase 2
33 Dermatologic Agents Phase 2
34 Vitamin B9 Phase 2,Phase 1
35 Antimetabolites Phase 2
36 Antiviral Agents Phase 2
37 Anti-Infective Agents Phase 2
38 Histone Deacetylase Inhibitors Phase 2
39 Angiogenesis Inhibitors Phase 2
40 Protein Kinase Inhibitors Phase 2,Phase 1
41 tyrosine Phase 2
42
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
43 Semaxinib Phase 2
44 Angiogenesis Modulating Agents Phase 2
45 Photosensitizing Agents Phase 2
46 Ether Phase 2
47 Dihematoporphyrin Ether Phase 2
48 Immunoglobulins Phase 2
49 Antibodies Phase 2
50 Antibodies, Monoclonal Phase 2

Interventional clinical trials:

(show all 23)
# Name Status NCT ID Phase Drugs
1 Video-Assisted Surgery or Talc Pleurodesis in Treating Patients With Malignant Mesothelioma Completed NCT00821860 Phase 3
2 Combination Chemotherapy With or Without Surgery and Chemoradiotherapy in Treating Patients With Malignant Pleural Mesothelioma Unknown status NCT00354393 Phase 2 cisplatin;methotrexate;vinorelbine ditartrate
3 S9810: Gemcitabine Plus Cisplatin in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot Be Removed by Surgery Completed NCT00003723 Phase 2 gemcitabine hydrochloride
4 PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery Completed NCT00365053 Phase 2 belinostat
5 S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery Completed NCT00243074 Phase 2 cediranib maleate
6 Gefitinib in Treating Patients With Malignant Mesothelioma Completed NCT00025207 Phase 2 gefitinib
7 Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung Completed NCT00039182 Phase 2 erlotinib hydrochloride
8 Pemetrexed Disodium and Cisplatin Followed By Surgery and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma Completed NCT00227630 Phase 2 cisplatin;pemetrexed disodium
9 Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma Completed NCT00509041 Phase 2 dasatinib
10 SU5416 in Treating Patients With Malignant Mesothelioma Completed NCT00006014 Phase 2 semaxanib
11 Surgery and Photodynamic Therapy in Treating Patients With Malignant Mesothelioma Completed NCT00054002 Phase 2 porfimer sodium
12 PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma Completed NCT00053885 Phase 2 PTK787/ZK 222584
13 Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery Completed NCT00309946 Phase 2 cediranib maleate
14 Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma Completed NCT00027703 Phase 2 gemcitabine hydrochloride;cisplatin
15 Capecitabine in Treating Patients With Malignant Mesothelioma Completed NCT00004183 Phase 2 capecitabine
16 Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma. Completed NCT00107432 Phase 2 sorafenib tosylate
17 Pemetrexed Disodium and Cisplatin Followed by Surgery With or Without Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma Completed NCT00334594 Phase 2 Cisplatin;Pemetrexed
18 Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma Active, not recruiting NCT01064648 Phase 1, Phase 2 Cediranib Maleate;Cisplatin;Pemetrexed Disodium
19 Pembrolizumab in Treating Patients With Malignant Mesothelioma Active, not recruiting NCT02399371 Phase 2
20 Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy Active, not recruiting NCT01085630 Phase 2 pemetrexed disodium
21 Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma Terminated NCT01861301 Phase 2 Tivantinib
22 AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma Withdrawn NCT01105390 Phase 2 cisplatin;pemetrexed disodium
23 Biomarkers of Angiogenesis and Disease in Patients With Unresectable Malignant Mesothelioma Treated on Clinical Trial CALGB-30107 Terminated NCT00898547

Search NIH Clinical Center for Sarcomatoid Mesothelioma

Sources

Genetic Tests for Sarcomatoid Mesothelioma

About this section
Sources

Anatomical Context for Sarcomatoid Mesothelioma

About this section

MalaCards organs/tissues related to Sarcomatoid Mesothelioma:

41
T Cells, Lung, Spinal Cord, Testis, Pancreas, Brain, Liver
Sources

Publications for Sarcomatoid Mesothelioma

About this section

Articles related to Sarcomatoid Mesothelioma:

(show all 35)
# Title Authors Year
1
Sarcomatoid mesothelioma of tunica vaginalis testis in the right scrotum of a dog. ( 29794371 )
2018
2
Invasive sarcomatoid mesothelioma resulting in spinal cord compression: case report. ( 30363152 )
2018
3
A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis. ( 30429020 )
2018
4
The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center. ( 28782639 )
2017
5
Evaluation of intracavitary administration of curcumin for the treatment of sarcomatoid mesothelioma. ( 28915695 )
2017
6
Primary malignant pericardial sarcomatoid mesothelioma: An autopsy report. ( 28463437 )
2017
7
MUC4, a novel immunohistochemical marker identified by gene expression profiling, differentiates pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma. ( 28128276 )
2017
8
Localized malignant pleural sarcomatoid mesothelioma misdiagnosed as benign localized fibrous tumor. ( 27293862 )
2016
9
Sarcomatoid mesothelioma: future advances in diagnosis, biomolecular assessment, and therapeutic options in a poor-outcomeA disease. ( 26108245 )
2015
10
Phrenic nerve paralysis as the initial presentation in pleural sarcomatoid mesothelioma. ( 25076889 )
2014
11
Connective tissue growth factor and I^-catenin constitute an autocrine loop for activation in rat sarcomatoid mesothelioma. ( 24839947 )
2014
12
Sarcomatoid mesothelioma with osteoid differentiation. ( 23945391 )
2013
13
Diagnostic usefulness of p16/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis. ( 23270897 )
2013
14
Primary malignant sarcomatoid mesothelioma in the pericardium. ( 23318857 )
2013
15
The effect of internalizing human single chain antibody fragment on liposome targeting to epithelioid and sarcomatoid mesothelioma. ( 21255833 )
2011
16
Pleomorphic epithelioid diffuse malignant pleural mesothelioma: a clinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma. ( 21358344 )
2011
17
Coarse pleural calcification in a mesothelioma patient raises the possibility of a rare tumour subtype: osteoblastic sarcomatoid mesothelioma. ( 21511743 )
2011
18
Sarcomatoid mesothelioma: a clinical-pathologic correlation of 326 cases. ( 20081811 )
2010
19
Choroid plexus metastases from pleural sarcomatoid mesothelioma. ( 18604744 )
2008
20
Podoplanin is a better immunohistochemical marker for sarcomatoid mesothelioma than calretinin. ( 18162779 )
2008
21
Differential diagnosis of sarcomatoid mesothelioma from true sarcoma and sarcomatoid carcinoma using immunohistochemistry. ( 18199156 )
2008
22
SYT-SSX fusion is absent in sarcomatoid mesothelioma allowing its distinction from synovial sarcoma of the pleura. ( 17507990 )
2007
23
Subcutaneous metastases of sarcomatoid mesothelioma with its differential diagnosis on fine needle aspiration--a case report. ( 16366102 )
2005
24
Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study. ( 12605647 )
2003
25
Anti-mesothelial markers in sarcomatoid mesothelioma and other spindle cell neoplasms. ( 10971698 )
2000
26
Pregnancy associated diffuse malignant fibrous mesothelioma of peritoneum. Immunohistochemical studies of ectopic decidual reaction and concomitant myofibroblastic and mesothelial proliferations. ( 9097717 )
1996
27
Malignant sarcomatoid mesothelioma of the pleura: a histological and immunohistological study of a case. ( 1923633 )
1991
28
Lymphohistiocytoid mesothelioma: a rare lymphomatoid variant of predominantly sarcomatoid mesothelioma. ( 2458647 )
1988
29
Three types of spindle cell tumors of the pleura. Fibroma, sarcoma, and sarcomatoid mesothelioma. ( 3421411 )
1988
30
Brain metastases in malignant fibrous mesothelioma. Case report and review of the literature. ( 6613538 )
1983
31
Malignant fibrous mesothelioma of the tunica vaginalis: a histologic and ultrastructural study. ( 870166 )
1977
32
Malignant fibrous mesothelioma. Metastatic to brain and liver. ( 1081808 )
1975
33
Ultrastructural studies of a malignant fibrous mesothelioma of the pleura. ( 5166103 )
1971
34
Malignant fibrous mesothelioma of peritoneum. ( 13472557 )
1957
35
Malignant fibrous mesothelioma of the peritoneum. ( 13106834 )
1953
Sources

Variations for Sarcomatoid Mesothelioma

About this section
Sources

Expression for Sarcomatoid Mesothelioma

About this section
Search GEO for disease gene expression data for Sarcomatoid Mesothelioma.
Sources

Pathways for Sarcomatoid Mesothelioma

About this section

Pathways related to Sarcomatoid Mesothelioma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Primary Focal Segmental Glomerulosclerosis FSGS 1
10.49 VIM WT1
Sources

GO Terms for Sarcomatoid Mesothelioma

About this section

Biological processes related to Sarcomatoid Mesothelioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription, DNA-templated GO:0045892 9.13 CDKN2A NKX2-1 WT1
2 positive regulation of gene expression GO:0010628 8.92 CDKN2A NKX2-1 VIM WT1
Sources

Sources for Sarcomatoid Mesothelioma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....